Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$3.09 - $4.56 $1,285 - $1,896
416 Added 18.93%
2,613 $10,000
Q4 2023

Feb 14, 2024

SELL
$2.8 - $3.35 $6,666 - $7,976
-2,381 Reduced 52.01%
2,197 $6,000
Q2 2023

Aug 10, 2023

BUY
$3.21 - $5.06 $14,695 - $23,164
4,578 New
4,578 $17,000
Q4 2022

Jun 14, 2023

BUY
$4.35 - $6.17 $21,436 - $30,405
4,928 New
4,928 $23.7 Million
Q3 2022

Jun 14, 2023

BUY
$5.49 - $8.79 $27,054 - $43,317
4,928 New
4,928 $28 Million
Q2 2022

Jun 20, 2023

BUY
$5.33 - $8.18 $26,266 - $40,311
4,928 New
4,928 $34,000
Q1 2022

Jun 20, 2023

BUY
$5.5 - $9.19 $27,104 - $45,288
4,928 New
4,928 $35,000
Q1 2022

Mar 30, 2023

SELL
$5.5 - $9.19 $76,686 - $128,136
-13,943 Reduced 73.89%
4,928 $35,000
Q1 2022

May 12, 2022

SELL
$5.5 - $9.19 $76,686 - $128,136
-13,943 Reduced 73.89%
4,928 $36,000
Q4 2021

Jun 21, 2023

BUY
$7.67 - $44.59 $144,740 - $841,457
18,871 New
18,871 $168,000
Q3 2021

Jun 21, 2023

BUY
$21.33 - $35.06 $402,518 - $661,617
18,871 New
18,871 $661,000
Q2 2021

Mar 30, 2023

BUY
$19.22 - $59.08 $273,885 - $841,890
14,250 Added 308.37%
18,871 $405,000
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $362,604 - $1.11 Million
18,866 Added 377320.0%
18,871 $405,000
Q1 2021

Jun 26, 2023

BUY
$41.42 - $88.44 $191,401 - $408,681
4,621 New
4,621 $285 Million
Q1 2021

Mar 30, 2023

SELL
$41.42 - $88.44 $9,360 - $19,987
-226 Reduced 4.66%
4,621 $285,000
Q1 2021

May 14, 2021

SELL
$41.42 - $88.44 $200,555 - $428,226
-4,842 Reduced 99.9%
5 $285,000
Q4 2020

Jun 22, 2023

BUY
$26.36 - $41.78 $127,766 - $202,507
4,847 New
4,847 $202,000
Q4 2020

Mar 30, 2023

SELL
$26.36 - $41.78 $2,135 - $3,384
-81 Reduced 1.64%
4,847 $202,000
Q4 2020

Feb 16, 2021

BUY
$26.36 - $41.78 $127,766 - $202,507
4,847 New
4,847 $203,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $288M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.